Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Robohogs who wrote (1659)	2/13/2002 5:20:25 PM
From: Qualified Opinion	Read Replies (1) \| Respond to of 10345

Elan forecasted between $1.55 and $1.65 EPS for the year 2002.

To: Robohogs who wrote (1659)	2/13/2002 5:21:42 PM
From: Qualified Opinion	Read Replies (1) \| Respond to of 10345

Elan is forecasting a growth in revenue. They are preparing for the long term.

To: Robohogs who wrote (1659)	2/13/2002 5:24:00 PM
From: biostruggle	Read Replies (2) \| Respond to of 10345

At this point Elan is only worth 18-20 on buy out. Non-liquid SPE, favorable Irish Tax treatment which may not transfer to acquirer and class action suits. Elan represents 1/3, or did represent 1/3 of my investments and retirement investments, I'd rather have a solid 18-20 in a more conservative Pharmaceutical company.

To: Robohogs who wrote (1659)	2/13/2002 5:29:31 PM
From: Icebrg	Read Replies (1) \| Respond to of 10345

Jon >> Earnings going from $1.91 to $1.30 (without acquired revenue) is not growing in my book.>> Oh, but they are growing their cost base and their capital expenditure. Because they are expanding their clinical programs, increasing the sales forces and manufacturing capabilities. All things which should really be expected from a company in Elan's situation. This is not yet a grown-up pharma, but more of an aspiring biotech. To grow in the clinics and on the sales field will require that cash is spent - there is no other way. Moodys might be right in their evaluation of the company's progress seen from a bond-holders point of view. That is however to most investors in biotech shares not a very interesting view of the business. Ice